Santo Baiamonte
👍 Impressed with the innovative approach and commitment to advancing gene editing. Satisfied with the quality and range of services and products. 👌
Jim Parr
Outstanding experience with this company! Their innovative approach and dedication to advancing gene editing technology are truly impressive. 👍
Jasmine Oneal
I have been using Cellectis for my genetic engineering projects for quite some time now and I have always been satisfied with their services. The team is knowledgeable and responsive, and the results have always been accurate. I highly recommend Cellectis for all genetic engineering needs.
Ted Dudek
I have used Cellectis for my genetic engineering projects and I couldn't be happier with the results. The quality of their work is top-notch and the team is extremely professional. I highly recommend this company for all genetic engineering needs. 👍
Rupar Iyar
🔥 Cellectis is my go-to company for all my genetic engineering needs. Their services are outstanding and their team is highly skilled. They always deliver exceptional results in a timely manner. I cannot recommend them enough!
Deb Settle
I've had a great experience working with Cellectis. Their genetic engineering services are outstanding and their team is highly skilled. The entire process, from consultation to project completion, was smooth and hassle-free. I would definitely choose Cellectis again. 👌
Cameron Lynch
I have been a customer of Cellectis for over a year now and I must say, their services are excellent. The staff is very knowledgeable and always ready to help. The website is user-friendly and easy to navigate. I would highly recommend Cellectis to anyone looking for genetic engineering services.
Danielle Thomas
I recently availed Cellectis' genetic engineering services and I must say, I'm impressed! They have a wide range of solutions that fit different needs. The team is friendly and always available for assistance. 👏 Highly recommended!
Glen Belden
The genetic engineering services provided by this company are excellent. I have used their services multiple times and they have never disappointed. The analysis reports are detailed and the turnaround time is impressive. Highly recommended!
Kathy Rostand
I'm really happy with the genetic engineering services provided by Cellectis. Their team is efficient, knowledgeable, and always ready to assist. The website is easy to navigate and the overall experience has been great. I would definitely choose Cellectis again for my future projects!
Gayla Mitchell
The services provided by Cellectis have been excellent. The team is knowledgeable, responsive, and delivers results on time. I'm really satisfied with their genetic engineering solutions. Highly recommend!
Sam Adeyemi
👍 Cellectis is a fantastic company to work with! Their services are top-notch and their team is extremely professional. They have a wide range of genetic engineering solutions that cater to various requirements. I'm really impressed with their work and would highly recommend them!
Gus Flick
I recently used a company to get my genome sequenced and I was very impressed with the results. The analysis provided by the company was detailed and accurate. The website was easy to use and the whole process was smooth. I would definitely recommend this company to others.
News
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
Widgets
Get the widget for your site →About Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer
Cellectis: Revolutionizing Cancer Treatment with Next-Generation CAR T-Cells
Cellectis is a clinical-stage biopharmaceutical company that is dedicated to developing innovative cancer treatments using the latest advancements in gene editing and cell therapy. The company's mission is to cure cancer by creating next-generation CAR T-cells that can effectively target and destroy cancer cells while leaving healthy cells unharmed.
Founded in 1999, Cellectis has been at the forefront of gene editing technology for over two decades. The company's expertise lies in its proprietary TALEN® gene-editing platform, which allows for precise modifications of genes within living cells. This technology has enabled Cellectis to develop a range of innovative therapies that have the potential to revolutionize cancer treatment.
One of Cellectis' most promising therapies is its Next-Generation CAR T-cells, which are designed to be more effective and safer than traditional CAR T-cell therapies. These new CAR T-cells are engineered using Cellectis' proprietary gene-editing technology, which allows for precise modifications of the immune system's T-cells so they can better recognize and attack cancer cells.
The potential benefits of these Next-Generation CAR T-cells are significant. Traditional CAR-T cell therapies have shown remarkable success in treating certain types of blood cancers but have limitations when it comes to solid tumors due to their inability to penetrate them effectively. However, with Cellectis' new approach, these limitations could be overcome as they aim at targeting solid tumors as well.
In addition, because these new CAR-T cells are engineered using a patient's own immune system cells rather than donor cells (as used by other companies), there is less risk of rejection or other adverse reactions from the body’s immune system.
Cellectis has already made significant progress towards bringing its Next-Generation CAR-T cell therapy into clinical use. In 2020 alone, the company announced positive results from several Phase I trials evaluating this therapy against various types of cancers such as Acute Myeloid Leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL). These results showed promising efficacy rates with manageable safety profiles.
Moreover, Cellectis has also entered into partnerships with leading pharmaceutical companies such as Pfizer Inc., Servier Laboratories SAS & Allogene Therapeutics Inc., who will help accelerate development efforts further while providing additional resources needed for commercialization purposes once approved by regulatory authorities worldwide.
In conclusion, Cellectis represents an exciting opportunity for investors looking for exposure in cutting-edge biotechnology companies focused on developing novel treatments against one of humanity’s deadliest diseases - Cancer! With its proprietary gene-editing platform and innovative approach towards developing next-generation cellular immunotherapies like Next Generation-CAR-T Cells; it could potentially change how we treat this disease forever!
- Website
- cellectis.com
- Categories
- Biotechnology